Citations

Showing 10 of 108083 citations.

Association of Pulmonary Hypertension and Monoclonal Gammopathy of Undetermined Significance
Lyle, Melissa , Bhatia, Subir , Fenstad, Eric R. , Schroeder, Darrell R. , McCully, Robert B. , Lacy, Martha Q. , Feyereisn, Wayne L. , Feyereisn, Wayne L. , Lyle, Melissa A , Fenstad, Eric , Schroeder, Darrell

Mayo Clinic

Advances in Hematology | November 18, 2022 | Volume: 2022 | Issue: No issue available | Pages: 1-8

10.1155/2022/8918959 | PMID 36438612 Get It

Objective. To determine the prevalence of monoclonal gammopathy of undetermined significance (MGUS) in patients with PH as well as precapillary PH. Methods. Olmsted County residents with PH, diagnosed between 1/1/1995 and 9/30/2017, were identified, and age and sex were matched to a normal control group. The PH group and normal control group were then cross-referenced with the Mayo Clinic MGUS database. Charts were reviewed to verify MGUS and PH. Heart catheterization data were then analyzed in these patients for reference to the gold standard for diagnosis. Results. There were 3419 patients diagnosed with PH by echocardiography between 1995 and 2017 in Olmsted County that met the criteria of our study. When the PH group (N = 3313) was matched to a normal control group (3313), a diagnosis of MGUS was significantly associated with PH 10.2% (OR = l.84 [95% CI 1.5–2.2], p < 0.001 ), compared with controls 5.8% based on echo diagnosis. Using heart catheterization data (484 patients), a diagnosis of MGUS was associated with PH 13.0% (OR = 3.94 [95% CI 2.28–6.82], p < 0.001 ). For pulmonary artery hypertension (N = 222), a diagnosis of MGUS was associated with PH at similar 12.2% (OR = 4.50 [95%CI 1.86–10.90], p < 0.001 . Conclusions. There is a higher prevalence of MGUS in patients with PH and precapillary PH compared with normal controls. This association cannot be explained fully by other underlying diagnoses associated with PH. Assessing for this in patients with PH of unclear etiology may be reasonable in the workup of patients found to have PH.
Deep Generative Networks for Algorithm Development in Implantable Neural Technology
Sladky, Vladimir , Balzekas, Irena , Pridalova, Tereza, Miller, Kai J. , Brinkmann, Benjamin H. , Brinkmann, Benjamin H , Mívalt, Filip , Gompel, Jamie J. Van , Denison, Timothy , Křemen, Václav , Worrell, Gregory A.

Mayo Clinic

2022 IEEE International Conference on Systems, Man, and Cybernetics (SMC) | November 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1736-1741

10.1109/smc53654.2022.9945379 Get It

Multicenter Registry Using Propensity Score Analysis to Compare a Novel Transport/Preservation System to Traditional Means on Postoperative Hospital Outcomes and Costs for Heart Transplant Patients
Leacche, Marzia , Copeland, Hannah , Shudo, Yasuhiro , Molina, Ezequiel J., Stukov, Yuriy , Philpott, Jonathan M. , Kawabori, Masashi , Schroder, Jacob N. , D’Alessandro, David, Molina, Ezequiel , Pham, Si M. , Voigt, Jeffrey , Wolfe, Stanley B. , Jacobs, Jeffrey P. , Meyer, Dan M , Silvestry, Scott

Mayo Clinic

ASAIO Journal | November 18, 2022 | Volume: 69 | Issue: 4 | Pages: 345-349

10.1097/mat.0000000000001844 | PMID 36399786 Get It

The standard method for cardiac allograft preservation for the past 50 years has been static storage using crushed ice. A heart transplant transportation system designed to improve preservation quality with temperature monitoring, the Paragonix SherpaPak Cardiac Transport System (SCTS), was evaluated for its impact on postoperative costs relative to conventional ice storage. Observational US multicenter registry data collected during the August 2015 to November 2021 timeframe from 12 transplant hospitals were analyzed using logistic regression analysis and propensity matching to balance measured baseline covariates and to reduce selection bias. Hospital cost and outcome data post-transplant were then evaluated using various statistical methods. One hundred seventy-four (174) patients were identified resulting in 87 matches. Baseline characteristics were similar between groups. The SCTS group had a significantly lower proportion of ICU days on post-transplant mechanical circulatory support ( p < 0.0001); significantly fewer patients on extracorporeal membrane oxygenation ( p = 0.017); and significantly fewer patients experiencing severe primary graft dysfunction (PGD) ( p = 0.03). Overall hospital plus mechanical circulatory support post-transplant costs were significantly lower by $26.7K in the CTS cohort ( p = 0.03). Use of the SCTS is associated with improved clinical outcomes resulting in significantly lower overall hospital care costs.
Direct electrical brain stimulation of human memory: lessons learnt and future perspectives
Axmacher, Nikolai , Kucewicz, Michał T. , Worrell, Gregory A.

Mayo Clinic

Brain | November 18, 2022 | Volume: 146 | Issue: 6 | Pages: 2214-2226

10.1093/brain/awac435 | PMID 36408731 Get It

Abstract Modulation of cognitive functions supporting human declarative memory is one of the grand challenges of neuroscience, and of vast importance for a variety of neuropsychiatric, neurodegenerative and neurodevelopmental diseases. Despite a recent surge of successful attempts at improving performance in a range of memory tasks, the optimal approaches and parameters for memory enhancement have yet to be determined. On a more fundamental level, it remains elusive as to how delivering electrical current in a given brain area leads to enhanced memory processing. Starting from the local and distal physiological effects on neural populations, the mechanisms of enhanced memory encoding, maintenance, consolidation or recall in response to direct electrical stimulation are only now being unravelled. With the advent of innovative neurotechnologies for concurrent recording and stimulation intracranially in the human brain, it becomes possible to study both acute and chronic effects of stimulation on memory performance and the underlying neural activities. In this review, we summarize the effects of various invasive stimulation approaches for modulating memory functions. We first outline the challenges that were faced in the initial studies of memory enhancement and the lessons learnt. Electrophysiological biomarkers are then reviewed as more objective measures of the stimulation effects than behavioural outcomes. Finally, we classify the various stimulation approaches into continuous and phasic modulation with an open or closed loop for responsive stimulation based on analysis of the recorded neural activities. Although the potential advantage of closed-loop responsive stimulation over the classic open-loop approaches is inconclusive, we foresee the emerging results from ongoing longitudinal studies and clinical trials will shed light on both the mechanisms and optimal strategies for improving declarative memory. Adaptive stimulation based on the biomarker analysis over extended periods of time is proposed as a future direction for obtaining lasting effects on memory functions. Chronic tracking and modulation of neural activities intracranially through adaptive stimulation opens tantalizing new avenues to continually monitor and treat memory and cognitive deficits in a range of brain disorders. Brain co-processors created with machine-learning tools and wireless bi-directional connectivity to seamlessly integrate implanted devices with smartphones and cloud computing are poised to enable real-time automated analysis of large data volumes and adaptively tune electrical stimulation based on electrophysiological biomarkers of behavioural states. Next-generation implantable devices for high-density recording and stimulation of electrophysiological activities, and technologies for distributed brain–computer interfaces are presented as selected future perspectives for modulating human memory and associated mental processes.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need
Pemmaraju, Naveen , Kantarjian, Hagop M. , Sweet, Kendra , Senapati, Jayastu , Konopleva, Marina , Frankel, Arthur E. , Gupta, Vikas , Ulrickson, Matthew L. , Gorak, Edward J., Bhatia, Sumeet, Budak-Alpdoǧan, Tülin , Mason, James R. , García‐Romero, María Teresa , López‐Santiago, Norma, Vachhani, Pankit , Lee, Sangmin , Blum, William , Walter, Roland B. , Bixby, Dale L. , Gojo, Ivana , Rampal, Raajit K. , Foran, James M. , Fathi, Amir T. , Hall, Aric C. , Jacoby, Meagan A., Mannis, Gabriel N. , Stein, Anthony S. , Rizzieri, David A. , Olin, Rebecca L. , Perl, Alexander E. , Schiller, Gary J. , Shami, Paul J. , Stone, Richard M. , Wieduwilt, Matthew J. , Vasu, Sumithira , Khoury, Joseph D. , Qazilbash, Muzaffar H. , Cuglievan, Branko , Madanat, Yazan F. , Kharfan‐Dabaja, Mohamed A. , Tallman, Martin S. , Dhakal, Prajwal , Senapati, Jayastu , Konopleva, Marina , Gupta, Vikas , Budak-Alpdogan, Tulin , Garcia-Romero, Maria Teresa , Cesarman-Maus, Gabriela , Vachhani, Pankit , Bhatt, Vijaya Raj , Walter, Roland B , Fathi, Amir T , Hall, Aric Cameron , Mims, Alice S , Rizzieri, David A , Perl, Alexander E , Strickland, Stephen Anthony , Daver, Naval , Guzmán, Mónica L. , Roboz, Gail J , Khoury, Joseph , Aung, Phyu P , Madanat, Yazan , Kharfan-Dabaja, Mohamed A , Pawlowska, Anna , Taylor, Justin , Dhakal, Prajwal , Lane, Andrew A , Kantarjian, Hagop , Wang, Eunice S. , Wilson, Nathaniel R. , Mesa, Ruben A. , Cesarman‐Maus, Gabriela , Bhatt, Vijaya Raj , Duvic, Madeleine , Lima, Marcos de , Lancet, Jeffrey E. , Daver, Naval , Ravandi, Farhad , Roboz, Gail J. , Lane, Andrew A.

Mayo Clinic

Blood | November 18, 2022 | Volume: 141 | Issue: 6 | Pages: 567-578

10.1182/blood.2022017865 | PMID 36399715 Get It

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC’s inaugural meetings are presented herein.
Integrated human-machine interface for closed-loop stimulation using implanted and wearable devices
Sladky, Vladimir , McQuown, Kevin, Brinkmann, Benjamin H. , Miller, Kai J. , Brinkmann, Benjamin H , Křemen, Václav , Mívalt, Filip , Gompel, Jamie J. Van , Denison, Timothy , Worrell, Gregory A.

Mayo Clinic

2022 IEEE International Conference on Systems, Man, and Cybernetics (SMC) | November 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1730-1735

10.1109/smc53654.2022.9945203 Get It

In Reply: A New Trend of Blended Learning in Neurosurgical Training: Fellowship of Neuroendoscopy
Ghozy, Sherief , Dmytriw, Adam A. , Dmytriw, Adam A , Ghozy, Sherief , Azzam, Ahmed Y

Mayo Clinic

Neurosurgery | November 18, 2022 | Volume: 92 | Issue: 1 | Pages: e13-e13

10.1227/neu.0000000000002216 | PMID 36399421 Get It

Glucocorticoids unmask silent non-coding genetic risk variants for common diseases
Nguyen, Thanh Thanh L. , Gao, Huanyao , Liu, Duan , Philips, Trudy Janice , Ye, Zhenqing, Lee, Jeong‐Heon , Shi, Geng‐Xian, Copenhaver, Kaleigh, Zhang, Lingxin , Yu, Jia , Zhang, Huan , Barath, Abhijeet S. , Luong, Maggie, Gaspar‐Maia, Alexandre , Wang, Liewei , Ördög, Tamás , Weinshilboum, Richard M. , Zhang, Huan , Barath, Abhijeet, Zhang, Cheng , Nguyen, Thanh Thanh L. , Lee, Jeong-Heon , Gaspar-Maia, Alexandre , Liu, Duan , Copenhaver, Kaleigh M. , Wei, Lixuan , Zhang, Cheng , Li, Hu , Weinshilboum, Richard M.

Mayo Clinic

Nucleic Acids Research | November 18, 2022 | Volume: 50 | Issue: 20 | Pages: 11635-11653

10.1093/nar/gkac1045 | PMID 36399508 Get It

Abstract Understanding the function of non-coding genomic sequence variants represents a challenge for biomedicine. Many diseases are products of gene-by-environment interactions with complex mechanisms. This study addresses these themes by mechanistic characterization of non-coding variants that influence gene expression only after drug or hormone exposure. Using glucocorticoid signaling as a model system, we integrated genomic, transcriptomic, and epigenomic approaches to unravel mechanisms by which variant function could be revealed by hormones or drugs. Specifically, we identified cis-regulatory elements and 3D interactions underlying ligand-dependent associations between variants and gene expression. One-quarter of the glucocorticoid-modulated variants that we identified had already been associated with clinical phenotypes. However, their affected genes were ‘unmasked’ only after glucocorticoid exposure and often with function relevant to the disease phenotypes. These diseases involved glucocorticoids as risk factors or therapeutic agents and included autoimmunity, metabolic and mood disorders, osteoporosis and cancer. For example, we identified a novel breast cancer risk gene, MAST4, with expression that was repressed by glucocorticoids in cells carrying the risk genotype, repression that correlated with MAST4 expression in breast cancer and treatment outcomes. These observations provide a mechanistic framework for understanding non-coding genetic variant-chemical environment interactions and their role in disease risk and drug response.
Health disparities in regional anesthesia and analgesia for the management of acute pain in trauma patients
Patton, John W., Burton, Brittany N. , Milam, Adam J. , Mariano, Edward R. , Gabriel, Rodney A. , Mariano, Edward R , Milam, Adam J

Mayo Clinic

International Anesthesiology Clinics | November 18, 2022 | Volume: 61 | Issue: 1 | Pages: 8-15

10.1097/aia.0000000000000382 | PMID 36398629 Get It

Quantifying muscle blood flow: a transformative breakthrough in the science of human exercise physiology
Olson, Thomas P. , Smith, Joshua R. , Curry, Timothy B. , Smith, Joshua R

Mayo Clinic

Clinical Science | November 18, 2022 | Volume: 136 | Issue: 22 | Pages: 1653-1656

10.1042/cs20220101 | PMID 36398719 Get It

Abstract Over 50 years ago, John Wahren and Lennart Jorfeldt published a manuscript in Clinical Science where they detailed a series of studies of leg blood flow during exercise. They used a novel approach to indicator dye dilution: continuous arterial infusions of dye using venous samples. This technique allowed them to describe for the first time the fundamental relationships between large muscle group exercise, muscle blood flow, and pulmonary and muscle oxygen uptake. They also defined mechanical efficiency, a key measurement of muscle function. This paper formed the basis for research into muscle blood flow and exercise in health and disease and continued to be cited by modern research. In this commentary, we describe the innovations they made, the key observations that came out of their results, and the importance of this manuscript to current research.